111 related articles for article (PubMed ID: 30430302)
1. The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
Morten BC; Chiu S; Oldmeadow C; Lubinski J; Scott RJ; Avery-Kiejda KA
Breast Cancer Res Treat; 2019 Feb; 173(3):727-733. PubMed ID: 30430302
[TBL] [Abstract][Full Text] [Related]
2. Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients.
Pouladi N; Kouhsari SM; Feizi MH; Dehghan R; Azarfam P; Farajzadeh D
Asian Pac J Cancer Prev; 2014; 15(6):2631-4. PubMed ID: 24761875
[TBL] [Abstract][Full Text] [Related]
3. Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley.
Malik MA; Sharma K; Goel S; Zargar SA; Mittal B
Oncol Res; 2011; 19(3-4):165-9. PubMed ID: 21473292
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects.
Sagne C; Marcel V; Amadou A; Hainaut P; Olivier M; Hall J
Cell Death Dis; 2013 Feb; 4(2):e492. PubMed ID: 23412385
[TBL] [Abstract][Full Text] [Related]
5. The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome.
Morten BC; Wong-Brown MW; Scott RJ; Avery-Kiejda KA
Carcinogenesis; 2016 Jan; 37(1):81-86. PubMed ID: 26586794
[TBL] [Abstract][Full Text] [Related]
6. Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population.
Marouf C; Tazzite A; Diakité B; Jouhadi H; Benider A; Nadifi S
Tumour Biol; 2014 Dec; 35(12):12403-8. PubMed ID: 25201062
[TBL] [Abstract][Full Text] [Related]
7. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
8. Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis.
Diakite B; Kassogue Y; Dolo G; Kassogue O; Keita ML; Joyce B; Neuschler E; Wang J; Musa J; Traore CB; Kamate B; Dembele E; Nadifi S; Isichei M; Holl JL; Murphy R; Doumbia S; Hou L; Maiga M
BMC Med Genet; 2020 Jul; 21(1):142. PubMed ID: 32620097
[TBL] [Abstract][Full Text] [Related]
9. Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma.
Qamar S; Khokhar MA; Farooq S; Ashraf S; Humayon WA; Rehman A
J Coll Physicians Surg Pak; 2019 Feb; 29(2):164-167. PubMed ID: 30700357
[TBL] [Abstract][Full Text] [Related]
10. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
[TBL] [Abstract][Full Text] [Related]
11. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
12. TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women.
Faghani M; Ghasemi FM; Nikhbakht M; Salehi M
Indian J Cancer; 2011; 48(3):298-302. PubMed ID: 21921327
[TBL] [Abstract][Full Text] [Related]
13. Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts.
Perriaud L; Marcel V; Sagne C; Favaudon V; Guédin A; De Rache A; Guetta C; Hamon F; Teulade-Fichou MP; Hainaut P; Mergny JL; Hall J
Carcinogenesis; 2014 Dec; 35(12):2706-15. PubMed ID: 25269805
[TBL] [Abstract][Full Text] [Related]
14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
16. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
19. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation.
Hao W; Xu X; Shi H; Zhang C; Chen X
Eur J Med Res; 2018 Oct; 23(1):47. PubMed ID: 30309383
[TBL] [Abstract][Full Text] [Related]
20. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
